Civitas' inhaled L-dopa Parkinson's treatment passes Phase I

Civitas Therapeutics generated positive top line results in a Phase I trial of CVT-301, its inhaled version of L-dopa to treat Parkinson's disease-related tremors. The drug, which is ingested through a hand-held inhaler, reached sufficient levels that support "its therapeutic potential," the Chelsea, MA, company said. Civitas' test on healthy volunteers was also shown to be safe and well-tolerated at many different dose levels, the company said. Civitas believes that the 40-year-old L-dopa drug will better maintain peak L-dopa plasma concentration than the more common oral delivery, which is not absorbed right away and can lead to variable plasma levels as well as debilitating Parkinson's symptoms. A grant from The Michael J. Fox Foundation for Parkinson's Research helped cover the cost. Release | Article

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.